Company Monitoring Page for Eli-Lilly

latest headlines for company on cafepharma

Lilly, Aduro Biotech in Immunotherapy Alliance
Contract Pharma
Thu, 12/20/18 - 11:46 am
Tags:
Eli Lilly, Aduro BioTech, autoimmune disease, drug development
Aiming to shed last-place rep, Eli Lilly touts its PhIII pipeline and promises a faster game in R&D
Endpoints
Wed, 12/19/18 - 10:06 am
Tags:
Eli Lilly, R&D
Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial
Reuters
Mon, 12/17/18 - 08:15 pm
Tags:
Eli Lilly, psoriatic arthritis, Taltz, AbbVie, Humira, clinical trials
Eli Lilly has anted up for its next big bet on a next-gen pain drug, buying Hydra assets
Endpoints
Mon, 12/17/18 - 09:00 am
Tags:
Eli Lilly, painkillers, Hydra Biosciences, TRPA-1
Mylan, Biocon copy inches closer to challenging Sanofi's long-suffering Lantus
Fierce Pharma
Thu, 12/13/18 - 12:24 pm
Tags:
Sanofi, Lantus, Eli Lilly, Boehringer Ingelheim, Mylan Labs, generics, diabetes, insulin, basal insulin
Lilly pays AC Immune $81M upfront for preclinical Alzheimer’s drug
Fierce Biotech
Wed, 12/12/18 - 11:49 am
Tags:
Eli Lilly, AC Immune, Alzheimer's disease, tau
Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design
Xtalks
Mon, 12/10/18 - 07:07 pm
Tags:
clinical trials, Multiple Myeloma, adaptive trial design, AbbVie, Celgene, Eli Lilly, Genentech, Janssen, Takeda
Eli Lilly's former drug yields Phase 2 win for Vanda Pharma
Biopharma Dive
Tue, 12/4/18 - 07:17 pm
Tags:
Vanda Pharmaceuticals, gastroparesis, clinical trials, Eli Lilly, tradipitant
Rising fear among Asians leads Eli Lilly to rethink employee groups
Indianpolis Business Journal
Sat, 11/24/18 - 01:25 pm
Tags:
Eli Lilly
Lilly CMO Robert Brown to lead Brickell Bio as it eyes phase 3 dermatology trials
Fierce Biotech
Mon, 11/19/18 - 04:46 pm
Tags:
Brickell Bio, Eli Lilly, Robert Brown, dermatology
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
BioSpace
Mon, 11/19/18 - 11:29 am
Tags:
cancer, breast cancer, lung cancer, drug approvals, AstraZeneca, Takeda, Ariad Pharmaceuticals, Merck, Pfizer, Novartis, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Puma Biotechnology, Mylan, Genentech
Eli Lilly Could Sell Some Older China Assets for up to $300 Million
BioSpace
Fri, 11/16/18 - 07:55 pm
Tags:
Eli Lilly, China
After historic win, Lilly partner Chi-Med’s Elunate flops in lung cancer
Fierce Pharma
Fri, 11/16/18 - 12:10 pm
Tags:
China MediTech, Elunate, Eli Lilly, China, non-small cell lung cancer
7 drugs that raised eyebrows in Q3
Biopharma Dive
Thu, 11/15/18 - 11:50 pm
Tags:
Sanofi, Dupixent, Roche, Herceptin, AbbVie, Humira, Regeneron, Repatha, Clovis Oncology, Rubraca, GSK, Shingrix, Eli Lilly, Trulicity
Lilly's third-to-market Emgality nets FDA 'breakthrough' in cluster headache
Fierce Pharma
Thu, 11/15/18 - 11:37 pm
Tags:
Eli Lilly, Emgality, cluster headaches, FDA, breakthrough therapies
Eli Lilly backs away from Bace but not from novel Alzheimer’s targets
EP Vantage
Thu, 11/15/18 - 09:48 am
Tags:
Eli Lilly, drug development, Alzheimer's disease, BACE inhibitors
Biotech Eli Lilly files for FDA approval of migraine drug lasmiditan
Fierce Biotech
Wed, 11/14/18 - 04:50 pm
Tags:
Eli Lilly, migraines, FDA, Lasmiditan
Viagra and Cialis: PDE-5 Inhibitors May Have Broader Applications in Cancer, Neurology and Cardiovascular Health
BioSpace
Wed, 11/14/18 - 09:56 am
Tags:
Viagra, Pfizer, Cialis, Eli Lilly, erectile dysfunction, cancer, Cardiovascular, drug repurposing
Fresh from Eli Lilly deal, NextCure bags $93M for clinical push
Fierce Biotech
Tue, 11/13/18 - 09:58 am
Tags:
NextCure, NC318, Eli Lilly
Eli Lilly sweeps the rest of the BACE work out of the pipeline following their latest major setback on Alzheimer’s
Endpoints
Wed, 11/7/18 - 07:17 pm
Tags:
Eli Lilly, Alzheimer's disease, BACE inhibitors

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.